Measles Antibody IgG

Measles is back. After being declared eliminated in many countries, outbreaks have returned, and a meaningful share of fully vaccinated adults turn out to have weaker protection than their records suggest. A blood test for measles IgG tells you whether your body has actually built lasting defenses, regardless of what your shot history says.

This matters because vaccine records get lost, immunity can wane over decades, and certain people (healthcare workers, those planning pregnancy, immunocompromised patients, anyone exposed during an outbreak) need to know their real status, not their presumed status.

What This Test Measures

Measles IgG (immunoglobulin G) is an antibody your immune system makes after exposure to the measles virus, either through natural infection or through MMR (measles, mumps, rubella) vaccination. It is produced largely by specialized immune cells called long-lived plasma cells that reside primarily in your bone marrow and continue secreting antibodies for years to decades after the initial exposure.

The presence of these antibodies in your blood reflects two things at once: a record of past exposure and an active line of defense. When measles virus enters your body, these IgG antibodies can neutralize it before it causes illness. Without them, your body has to start from scratch, which is when severe disease tends to happen.

Susceptibility to Measles Infection

Low or absent measles IgG is the most direct sign that you could catch measles if exposed. Population data from European seroprevalence studies show that the age groups with the lowest IgG levels are the ones in which outbreaks tend to occur, with seronegativity rates of roughly 13 to 20 percent in cohorts born after 1990 in some countries. Even fully vaccinated young adults can fall into this gap.

An Italian study of 2,000 medical students and residents who had received two documented MMR doses found that 15 percent lacked protective IgG about 10 years after vaccination. A European meta-analysis of healthcare workers found 13.3 percent were considered IgG-susceptible. The pattern is consistent: a two-dose vaccine record does not guarantee that your current antibody level still protects you.

Vaccine Failure and Breakthrough Infection

Some people are vaccinated, develop protective antibodies, and still see those antibodies wane below useful levels over time. This is called secondary vaccine failure. During the 2011 New York City outbreak, measles occurred in people with documented two-dose vaccination, including some with previously positive IgG. The presence of any IgG is not the same as sterilizing immunity, and borderline levels are associated with higher risk of clinical disease.

Antibodies from natural infection (in people born before the vaccine era) tend to be much higher and more durable than antibodies from vaccination alone. This is why immunity gaps cluster in younger, vaccinated-only adults rather than in older people who had childhood measles.

Infant Vulnerability Through Maternal Antibodies

If you are pregnant or planning pregnancy, your measles IgG matters for your baby as well as for you. IgG crosses the placenta, giving the newborn temporary protection. But that protection drops fast. A Belgian study found that infants of vaccinated mothers had measurable maternal antibodies for a median of only about 1 month, compared to nearly 4 months for infants of naturally immune mothers.

An Indian cohort tracked the same decline more dramatically: protective IgG fell sharply between birth and 6 to 9 months of age. By six months of age, most infants were susceptible. This is the window in which infants are most likely to die from measles if exposed, and your own antibody level shapes how short or long that window is.

Multiple Sclerosis and the MRZ Reaction

There is one specialized use of measles IgG that confuses most people who see it ordered. In suspected multiple sclerosis (MS), neurologists measure measles IgG in the cerebrospinal fluid (the fluid around your brain and spinal cord) alongside antibodies to rubella and varicella zoster. This panel, called the MRZ reaction, is one of the most specific laboratory markers for MS. A positive result reflects chronic immune activation inside the central nervous system, not active measles infection.

This finding may seem to contradict the rest of the story, where measles IgG simply means protection. The two are consistent once you separate the location: measles IgG in your blood reflects normal immunity, while measles IgG made locally inside the brain and spinal cord reflects a different process tied to MS. If you are getting a standard blood test, the MRZ reaction is not relevant, but it explains why neurologists sometimes order measles antibody studies on cerebrospinal fluid.

Why a Single Reading Is Not the End of the Story

Measles IgG is not the kind of biomarker you trend monthly, because the underlying biology is slow. But a single reading is still a snapshot, and immunity can change in ways that a one-time test cannot capture. After MMR vaccination, antibody levels rise sharply within weeks and then slowly decline over years. After natural infection, they stay high for decades. Without periodic checks, you may not notice that you have drifted into the susceptible range.

Current ACIP guidelines accept two documented MMR doses as evidence of immunity and do not require periodic serologic retesting. Beyond that baseline, a more cautious approach (not part of standard guidelines) is to get a baseline measurement now, retest about 4 to 6 weeks after any MMR booster to confirm a response, and consider rechecking every few years if you fall into a higher-risk group (healthcare worker, frequent international traveler, planning pregnancy, immunocompromised, or living in an area with active outbreaks). Most people with a clearly protective result do not need to repeat the test on a fixed schedule, but if your initial value is borderline or negative, retesting after a booster is the only way to verify that you have actually built protection.

When Results Can Be Misleading

Several factors can make a single measles IgG reading look better or worse than your true biological status:

• Recent IVIG (intravenous immunoglobulin) therapy: treatment for primary immune deficiency or other conditions contains donor measles antibodies. This can make a person appear immune from passive antibody alone, not from their own response.
• B-cell depleting drugs: medications like rituximab, ocrelizumab, and similar monoclonal antibodies used in MS, rheumatoid arthritis, and certain cancers can lower IgG levels generally and blunt new vaccine responses. A low reading on these drugs may reflect the medication, not loss of true memory.
• Assay differences: different labs use different test kits and reporting units. A borderline result on one test may be clearly protective on another.
• Recent acute infection or vaccination: if you were just exposed to measles or just received a booster, IgG will be rising quickly and may not reflect your stable steady-state level for several weeks.

What to Do If Your Result Is Low or Borderline

A negative or borderline measles IgG does not mean you are about to get sick. It means you should treat yourself as potentially susceptible and act accordingly. The standard next step is to get an MMR booster (or complete the two-dose series if you only had one), then retest 4 to 6 weeks later to confirm your response. Most people respond well to a single additional dose, even those who initially appeared unprotected.

If you do not mount a response after revaccination, that is worth investigating further with your doctor. Persistent inability to make measles antibodies after multiple doses can point to an underlying immune issue and may warrant referral to an allergist-immunologist. If you are immunocompromised and cannot be safely vaccinated, knowing you are susceptible matters during outbreaks, when post-exposure immunoglobulin can prevent severe disease.